Physician profile
Daniel Paul Lee
NPI 1720460181
$2,288.71
in general payments reported to CMS, 2019-2025
21 companies · $682 in 2025
The $682 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $157 · 2021: $342 · 2022: $279 · 2023: $403 · 2024: $426 · 2025: $682.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,493 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,493.45 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $505.14 | 2019-2025 | Simbrinza, Unity, Eysuvis |
| Tarsus Pharmaceuticals, INC. | $341.14 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $248.08 | 2021-2023 | |
| Amgen INC. | $163.90 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $161.87 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $158.35 | 2022-2025 | Oxervate |
| Xeris Pharmaceuticals, INC. | $124.01 | 2023 | Gvoke Hypopen |
| Oyster Point Pharma, INC. | $112.69 | 2022-2025 | Tyrvaya |
| Biotissue Holdings INC. | $107.96 | 2021-2022 | |
| Rayner Intraocular Lenses Limited | $75.09 | 2024-2025 | Omidria, Rayone Emv, Rayone Spheric |
| Sight Sciences, INC. | $61.40 | 2024-2025 | Omni Surgical System |
| Horizon Therapeutics Plc | $43.39 | 2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $28.66 | 2022-2024 | Tecnis Iol |
| Boston Scientific Corporation | $26.87 | 2022 | |
| Aerie Pharmaceuticals, INC. | $25.76 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $25.41 | 2024 | |
| Omeros Corporation | $19.50 | 2021 | |
| Eyevance Pharmaceuticals LLC | $18.08 | 2022 | |
| Kala Pharmaceuticals, INC. | $15.39 | 2021 | |
| Shire North American Group INC | $13.05 | 2019 | |
| Ivantis, INC | $12.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.